Revenue
2018
2019
2020
2021
2022
2023
2024
2025
BIO-RAD LABORATORIES, INC. (BIO)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B | $2.55B | $2.31B | $2.29B | $2.16B | $2.07B | $2.02B | $2.18B | $2.13B | $2.07B | $2.07B | $1.93B | $1.78B | $1.76B |
| Gross profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B | $1.44B | $1.26B | $1.22B | $1.19B | $1.14B | $1.12B | $1.18B | $1.18B | $1.16B | $1.18B | $1.09B | $999.8M | $962.5M |
| Research & development | $275.6M | $295.9M | $247.4M | $256.9M | $260.6M | $217.8M | $202.7M | $199.2M | $250.2M | $205.7M | $193.0M | $220.3M | $211.0M | $209.2M | $177.6M | $172.3M | $163.6M | $159.5M |
| Operating income | $47.2M | $269.0M | $337.8M | $482.6M | $500.3M | $421.3M | $229.7M | −$103.3M | $119.3M | $55.7M | $166.7M | $150.0M | $169.5M | $264.2M | $305.2M | $284.0M | $231.0M | $182.9M |
| EBITDAderived | $212.6M | $420.6M | $483.7M | $619.9M | $637.9M | $559.9M | $363.9M | $34.8M | $267.9M | $198.6M | $298.5M | $299.9M | $316.7M | $394.6M | $426.2M | $392.9M | $332.7M | — |
| Net income | $759.9M | −$1.84B | −$637.3M | −$3.63B | $4.25B | $3.81B | $1.76B | $365.6M | $122.2M | $26.0M | $109.2M | $88.8M | $77.8M | $165.5M | $179.0M | $185.5M | $144.6M | $89.5M |
| Basic EPSper diluted share | $27.87 | -$65.36 | -$21.82 | -$121.79 | $142.61 | $128.13 | $58.93 | $12.25 | $4.12 | $0.88 | $3.74 | $3.08 | $2.72 | $5.85 | $6.39 | $6.70 | $5.28 | $3.30 |
| Diluted EPSper diluted share | $27.85 | -$65.36 | -$21.82 | -$121.79 | $140.83 | $126.47 | $58.27 | $12.10 | $4.07 | $0.88 | $3.71 | $3.05 | $2.69 | $5.78 | $6.29 | $6.59 | $5.20 | $3.24 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 11, 2026Form 4 | ENGELHARDT EVA ANETTEEVP, President, CDG | SellBio-Rad A Common Stock | 550 | $246.54 | $135.6K | 346 |
| Nov 6, 2025Form 4 | BARRY JAMESEVP, President, LSG | SellBio-Rad A Common Stock | 699.87 | $306.18 | $214.3K | 509.68 |
| Mar 14, 2025Form 4 | Crowley MichaelEVP, GBL Commercial Operations | SellBio-Rad A Common Stock | 3.0K | $247.06 | $741.2K | 8.2K |
| Sep 6, 2024Form 4 | Last Andrew J.EVP, Chief Operating Officer | SellBio-Rad A Common Stock | 3.0K | $329.94 | $989.8K | 7.6K |
| Sep 4, 2024Form 4 | BARRY JAMESEVP, President, LSG | SellBio-Rad A Common Stock | 623 | $330.49 | $205.9K | 146.56 |